The Patent That Has SciSparc Shares Surging Tuesday

SciSparc Ltd SPRC shares are trading higher Tuesday after the company announced it was granted a European patent for its core technology.

What Happened: The European Patent Office granted SciSparc a new patent titled, "Combinations of Cannabinoids and N-Acylethanolamines."

The patent is related to methods for potentiating therapeutic effects and reducing side-effects of certain cannabinoids in the cannabis plant and provides for use in multiple indications amenable to treatment with cannabinoids.

"We continue to believe that cannabinoid-based medicines have enormous therapeutic potential and therefore we continue to strengthen the patent protection around the technologies we develop," said Oz Adler, CEO of SciSparc.

SciSparc is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system. The company implemented a 1-for-26 reverse split last week. 

See Also: Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More

SPRC Price Action: SciSparc shares were up 34.5% at $4.95 at the time of publication, according to Benzinga Pro.

Photo: Pexels from Pixabay.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!